NCT07359040ACTIVE_NOT_RECRUITING

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

Mechanisms of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

Sponsor: Peking University People's Hospital

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Request endpoint coverage

Key Facts

Study type

OBSERVATIONAL

Conditions

Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors, Immunotherapy

Interventions

Ivonescimab, PD-1 Inhibitors

Enrollment

80 participants

Primary completion

Dec 2026

Study completion

Oct 2027

First posted

Jan 2026

Last updated

Mar 2026

Primary Endpoints (CT.gov)

Pathological Complete Response (pCR

Time frame: At surgery (typically 3-6 months post-treatment initiation)

Secondary Endpoints

Major Pathological Response (MPR)

Objective Response Rate (ORR)

Event-free Survival (EFS)

Eligibility Criteria

Inclusion Criteria: Patients with non-small cell lung cancer (Stage IB-IIIB) who require radical surgery following neoadjuvant therapy. Exclusion Criteria: 1. Histology of other malignant tumors, including concurrent malignant tumors of other organ systems; 2. Unresectable advanced disease (Stage IV) or locally advanced unresectable (Stage IIIC); 3. Pregnancy or lactation; 4. Insufficient sample quality; 5. Severe organ dysfunction (e.g. cardiac or renal insufficiency); 6. Other judgments by the Investigator that the patient should not participate in the study.

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Request coverage →

Source

Open on ClinicalTrials.gov